BCR/ABL amplification in CML blast crisis following STI571 administration.

被引：0
作者：
Campbell, LJ
Patsouris, C
Rayeroux, KC
Somana, K
Januszewicz, H
机构：
[1] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4435
引用
收藏
页码：185B / 185B
页数：1
相关论文
共 50 条
[31]   Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines [J].
van der Kuip, H ;
Moehring, A ;
Wohlbold, L ;
Miething, C ;
Duyster, J ;
Aulitzky, WE .
LEUKEMIA RESEARCH, 2004, 28 (04) :405-408
[32]   STI571 reverses the mutator phenotype induced by Bcr-Abl in murine cell lines. [J].
van der Kuip, H ;
Miething, C ;
Duyster, J ;
Aulitzky, WE .
BLOOD, 2001, 98 (11) :571A-571A
[33]   STI571, a molecularly targeted treatment modality for CML. [J].
Buchdunger, E ;
Peng, B ;
Ford, J ;
Capdeville, R ;
Resta, D ;
Druker, B ;
Sawyers, C ;
Talpaz, M .
CLINICAL CANCER RESEARCH, 2000, 6 :4482S-4482S
[34]   Trial of IFN or STI571 before proceeding to allografting for CML? [J].
R Hehlmann .
Leukemia, 2000, 14 :1560-1562
[35]   Kinetics of BCR/ABL fusion transcript levels in CML patients treated with STI571 as measured by real-time quantitative (RQ) PCR. [J].
Stentoft, J ;
Pallisgaard, N ;
Kjeldsen, E ;
Nielsen, JL ;
Hokland, P .
BLOOD, 2001, 98 (11) :320A-320A
[36]   Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571 [J].
Gambacorti-Passerini, C ;
Barni, R ;
le Coutre, P ;
Zucchetti, M ;
Cabrita, G ;
Cleris, L ;
Rossi, F ;
Gianazza, E ;
Brueggen, J ;
Cozens, R ;
Pioltelli, P ;
Pogliani, E ;
Corneo, G ;
Formelli, F ;
D'Incalci, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (20) :1641-1650
[37]   Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) [J].
Wohlbold, L ;
van der Kuip, H ;
Miething, C ;
Vornlocher, HP ;
Knabbe, C ;
Duyster, J ;
Aulitzky, WE .
BLOOD, 2003, 102 (06) :2236-2239
[38]   PCR-negative molecular remissions in chronic-, accelerated-, and blast crisis-phase CML patients treated with STI571, an ABL-specific kinase inhibitor [J].
Shah, NP ;
Snyder, DS ;
Nicoll, JM ;
McMahon, RJ ;
Hsu, NC ;
Forman, SJ ;
Ford, JM ;
Sawyers, CL ;
Paquette, RL .
BLOOD, 2000, 96 (11) :471A-471A
[39]   Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes [J].
Czechowska, A ;
Poplawski, T ;
Drzewoski, J ;
Blasiak, J .
CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 152 (2-3) :139-150
[40]   Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia [J].
Shah, NP ;
Nicoll, JM ;
Nagar, B ;
Gorre, ME ;
Paquette, RL ;
Kuriyan, J ;
Sawyers, CL .
CANCER CELL, 2002, 2 (02) :117-125
12345